Modality
Multispecific
MOA
Anti-Tau
Target
IL-13
Pathway
Amyloid
PompeEpilepsyObesity
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
~Nov 2018
→ ~Feb 2020
Phase 2
May 2020
→ Jan 2026
Phase 2Current
NCT07833768
1,492 pts·Pompe
2020-05→2026-01·Active
1,492 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-202mo agoPh3 Readout· Pompe
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P2/3
Active
Catalysts
Ph3 Readout
2026-01-20 · 2mo ago
Pompe
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07833768 | Phase 2/3 | Pompe | Active | 1492 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA |